阴道黄体酮在辅助生殖技术周期中黄体期支持的临床疗效系统综述
该系统综述检索MEDLINE、Embase和Cochrane图书馆(截至2016年6月30日),纳入18项头对头随机对照试验,比较Crinone、Cyclogest、Lutigest和Utrogestan Vaginal等阴道黄体酮制剂在辅助生殖技术周期中黄体期支持的有效性或安全性。结果显示Utrogestan Vaginal与Crinone的临床妊娠率无显著差异,Utrogestan Vaginal和Lutigest在持续妊娠率方面非劣于Crinone,患者报告的会阴刺激在Crinone和Lutigest与Cyclogest比较中无显著差异,提示这些制剂是同等安全有效的选择。
要点
- Utrogestan Vaginal与Crinone的临床妊娠率无显著差异
- Utrogestan Vaginal和Lutigest在持续妊娠率方面非劣于Crinone
- Crinone和Lutigest与Cyclogest的会阴刺激无显著差异
核心结论
- Crinone、Cyclogest、Lutigest和Utrogestan Vaginal是辅助生殖技术周期中黄体期支持的同等安全有效的阴道黄体酮选择。
- 未来的定量分析可进一步支持这些发现。
研究设计与样本
- 系统综述检索MEDLINE、Embase和Cochrane图书馆数据库,检索日期为2016年6月30日。
- 纳入18项头对头随机对照试验,比较阴道黄体酮制剂(Crinone、Cyclogest、Lutigest或Utrogestan Vaginal)在辅助生殖技术周期中黄体期支持的有效性或安全性。
主要发现
- Utrogestan Vaginal与Crinone比较,临床妊娠率无显著差异。
- Utrogestan Vaginal和Lutigest在持续妊娠率比较中非劣于Crinone。
- Crinone和Lutigest与Cyclogest比较,患者报告的会阴刺激差异无显著差异。
- 在比较Utrogestan Vaginal或Crinone不同时机或剂量的研究中,未观察到显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaginal progesterone via capsule, gel or tablet is the most common route for luteal phase support (LPS) in Europe. Although there is a wealth of data comparing products used at other stages of assisted reproductive technology cycles, there is a lack of systematically identified evidence comparing the wide range of vaginal progesterone products. This systematic review queried the MEDLINE, Embase and Cochrane Library databases on 30 June 2016 to identify head-to-head randomized controlled trials (RCTs) comparing the efficacy or safety of vaginal progesterone preparations (Crinone, Cyclogest, Lutigest or Utrogestan Vaginal) for LPS in assisted reproductive technology cycles. Of 1914 results, 18 RCTs were included. No significant difference in clinical pregnancy rate was identified in comparisons of Utrogestan Vaginal with Crinone. Utrogestan Vaginal and Lutigest were non-inferior to Crinone in ongoing pregnancy rate comparisons. Differences in patient-reported perineal irritation with Crinone and Lutigest were not significantly different to Cyclogest. In studies comparing varying timing or dosage of Utrogestan Vaginal or Crinone, no significant differences were observed. These results suggest Crinone, Cyclogest, Lutigest and Utrogestan Vaginal represent equally safe and effective choices of vaginal progesterone for LPS in assisted reproductive technology cycles. Future quantitative analyses could provide further support for these findings.
引用
- Child T, Leonard SA, Evans JS, et al. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online. 2018. PMID: 29550390. doi:10.1016/j.rbmo.2018.02.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。